{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:58:51Z","timestamp":1790481531596,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76711-0","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:37:32Z","timestamp":1787629052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma"],"prefix":"10.1038","volume":"17","author":[{"given":"Marilena","family":"Tauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-0429","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneeth R.","family":"Sudalagunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0259-1875","authenticated-orcid":false,"given":"Mark","family":"Meads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Renatino","family":"Canevarolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-2220","authenticated-orcid":false,"given":"Niveditha","family":"Nerlakanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghunandan R.","family":"Alugubelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-7775","authenticated-orcid":false,"given":"Harshani R.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9230-7533","authenticated-orcid":false,"given":"Mukund P.","family":"Tantak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gunawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Nareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Young","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1342-7620","authenticated-orcid":false,"given":"Timothy H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-2558","authenticated-orcid":false,"given":"Nicholas J.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Sch\u00f6nbrunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9065","authenticated-orcid":false,"given":"John L.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-9986","authenticated-orcid":false,"given":"Ariosto S.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-6244","authenticated-orcid":false,"given":"Conor C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"76711_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jbo.2018.09.001","volume":"13","author":"J Adamik","year":"2018","unstructured":"Adamik, J., Galson, D. L. & Roodman, G. D. Osteoblast suppression in multiple myeloma bone disease. J. Bone Oncol. 13, 62\u201370 (2018).","journal-title":"J. Bone Oncol."},{"key":"76711_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","volume":"75","author":"MR Reagan","year":"2015","unstructured":"Reagan, M. R., Liaw, L., Rosen, C. J. & Ghobrial, I. M. Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone 75, 161\u2013169 (2015).","journal-title":"Bone"},{"key":"76711_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M. & Dimopoulos, M. A. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 8, 7 (2018).","journal-title":"Blood Cancer J."},{"key":"76711_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau, P. et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120, 947\u2013959 (2012).","journal-title":"Blood"},{"key":"76711_CR5","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137, 2890\u20132901 (2021).","journal-title":"Blood"},{"key":"76711_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"New Engl. J. Med."},{"key":"76711_CR7","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.3390\/ijms24076019","volume":"24","author":"H Bashiri","year":"2023","unstructured":"Bashiri, H. & Tabatabaeian, H. Autophagy: a potential therapeutic target to tackle drug resistance in multiple myeloma. Int. J. Mol. Sci. 24, 6019 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"76711_CR8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.ajem.2020.07.030","volume":"38","author":"A Della Porta","year":"2020","unstructured":"Della Porta, A. et al. Acute chloroquine and hydroxychloroquine toxicity: a review for emergency clinicians. Am. J. Emerg. Med. 38, 2209\u20132217 (2020).","journal-title":"Am. J. Emerg. Med."},{"key":"76711_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106057","volume":"56","author":"K Mubagwa","year":"2020","unstructured":"Mubagwa, K. Cardiac effects and toxicity of chloroquine: a short update. Int. J. Antimicrob. Agents 56, 106057 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"76711_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00296-021-04868-6","volume":"41","author":"R Muller","year":"2021","unstructured":"Muller, R. Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. Rheumatol. Int. 41, 1189\u20131202 (2021).","journal-title":"Rheumatol. Int."},{"key":"76711_CR11","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1074\/jbc.M115.689646","volume":"291","author":"C Puente","year":"2016","unstructured":"Puente, C., Hendrickson, R. C. & Jiang, X. Nutrient-regulated phosphorylation of ATG13 inhibits starvation-induced autophagy. J. Biol. Chem. 291, 6026\u20136035 (2016).","journal-title":"J. Biol. Chem."},{"key":"76711_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1083\/jcb.201403009","volume":"206","author":"R Chen","year":"2014","unstructured":"Chen, R. et al. The general amino acid control pathway regulates mTOR and autophagy during serum\/glutamine starvation. J. Cell Biol. 206, 173\u2013182 (2014).","journal-title":"J. Cell Biol."},{"key":"76711_CR13","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1111\/febs.13906","volume":"283","author":"CR Braden","year":"2016","unstructured":"Braden, C. R. & Neufeld, T. P. Atg1-independent induction of autophagy by the Drosophila Ulk3 homolog, ADUK. FEBS J. 283, 3889\u20133897 (2016).","journal-title":"FEBS J."},{"key":"76711_CR14","doi-asserted-by":"publisher","first-page":"112782","DOI":"10.1016\/j.ejmech.2020.112782","volume":"208","author":"D Sun","year":"2020","unstructured":"Sun, D. et al. Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer. Eur. J. Med. Chem. 208, 112782 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"76711_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/10799893.2019.1638401","volume":"39","author":"P Mu","year":"2019","unstructured":"Mu, P. & Karuppasamy, R. Discovery of human autophagy initiation kinase ULK1 inhibitors by multi-directional in silico screening strategies. J. Recept. Signal Transduct. Res. 39, 122\u2013133 (2019).","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"76711_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1021\/cb500835z","volume":"10","author":"MB Lazarus","year":"2015","unstructured":"Lazarus, M. B., Novotny, C. J. & Shokat, K. M. Structure of the human autophagy initiating kinase ULK1 in complex with potent inhibitors. ACS Chem. Biol. 10, 257\u2013261 (2015).","journal-title":"ACS Chem. Biol."},{"key":"76711_CR17","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06547","volume":"4","author":"A Caballe","year":"2015","unstructured":"Caballe, A. et al. ULK3 regulates cytokinetic abscission by phosphorylating ESCRT-III proteins. eLife 4, e06547 (2015).","journal-title":"eLife"},{"key":"76711_CR18","doi-asserted-by":"publisher","first-page":"30079","DOI":"10.1074\/jbc.M110.133991","volume":"285","author":"A Maloverjan","year":"2010","unstructured":"Maloverjan, A. et al. Dual function of UNC-51-like kinase 3 (ULK3) in the Sonic Hedgehog signaling pathway. J. Biol. Chem. 285, 30079\u201330090 (2010).","journal-title":"J. Biol. Chem."},{"key":"76711_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.535","volume":"5","author":"E Pantazi","year":"2014","unstructured":"Pantazi, E. et al. GLI2 induces genomic instability in human keratinocytes by inhibiting apoptosis. Cell Death Dis. 5, e1028 (2014).","journal-title":"Cell Death Dis."},{"key":"76711_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2006.06.001","volume":"10","author":"K Degenhardt","year":"2006","unstructured":"Degenhardt, K. et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10, 51\u201364 (2006).","journal-title":"Cancer Cell"},{"key":"76711_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/nrc2254","volume":"7","author":"R Mathew","year":"2007","unstructured":"Mathew, R., Karantza-Wadsworth, V. & White, E. Role of autophagy in cancer. Nat. Rev. Cancer 7, 961\u2013967 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"76711_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36410-6","volume":"14","author":"S Goruppi","year":"2023","unstructured":"Goruppi, S. et al. The ULK3 kinase is a determinant of keratinocyte self-renewal and tumorigenesis targeting the arginine methylome. Nat. Commun. 14, 887 (2023).","journal-title":"Nat. Commun."},{"key":"76711_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3390\/genes11121453","volume":"11","author":"M Sessa","year":"2020","unstructured":"Sessa, M., Cavazzini, F., Cavallari, M., Rigolin, G. M. & Cuneo, A. A tangle of genomic aberrations drives multiple myeloma and correlates with clinical aggressiveness of the disease: a comprehensive review from a biological perspective to clinical trial results. Genes 11, 1453 (2020).","journal-title":"Genes"},{"key":"76711_CR24","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/0008-5472.CAN-22-2350","volume":"83","author":"KL Burger","year":"2023","unstructured":"Burger, K. L. et al. CK1\u03b4 and CK1\u03b5 signaling sustains mitochondrial metabolism and cell survival in multiple myeloma. Cancer Res. 83, 3901\u20133919 (2023).","journal-title":"Cancer Res."},{"key":"76711_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/0008-5472.CAN-21-1168","volume":"82","author":"MR Fernandez","year":"2022","unstructured":"Fernandez, M. R. et al. Disrupting the MYC-TFEB circuit impairs amino acid homeostasis and provokes metabolic anergy. Cancer Res. 82, 1234\u20131250 (2022).","journal-title":"Cancer Res."},{"key":"76711_CR26","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","volume":"23","author":"DS Das","year":"2017","unstructured":"Das, D. S. et al. Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells. Clin. Cancer Res. 23, 4280\u20134289 (2017).","journal-title":"Clin. Cancer Res."},{"key":"76711_CR27","doi-asserted-by":"publisher","first-page":"85392","DOI":"10.18632\/oncotarget.19907","volume":"8","author":"H Bai","year":"2017","unstructured":"Bai, H., Wu, S., Wang, R., Xu, J. & Chen, L. Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease. Oncotarget 8, 85392\u201385400 (2017).","journal-title":"Oncotarget"},{"key":"76711_CR28","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202004182","volume":"220","author":"ME Bischoff","year":"2021","unstructured":"Bischoff, M. E. et al. Selective MAP1LC3C (LC3C) autophagy requires noncanonical regulators and the C-terminal peptide. J. Cell Biol. 220, e202010075 (2021).","journal-title":"J. Cell Biol."},{"key":"76711_CR29","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-16-0568-T","volume":"16","author":"SW Ember","year":"2017","unstructured":"Ember, S. W. et al. Potent dual BET bromodomain-kinase inhibitors as value-added multitargeted chemical probes and cancer therapeutics. Mol. Cancer Ther. 16, 1054\u20131067 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"76711_CR30","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","volume":"64","author":"RR Davis","year":"2021","unstructured":"Davis, R. R. et al. Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof. J. Med. Chem. 64, 2228\u20132241 (2021).","journal-title":"J. Med. Chem."},{"key":"76711_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/ejh.13141","volume":"101","author":"HEH Moller","year":"2018","unstructured":"Moller, H. E. H. et al. Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma. Eur. J. Haematol. 101, 585\u2013593 (2018).","journal-title":"Eur. J. Haematol."},{"key":"76711_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2011.53","volume":"25","author":"WJ Chng","year":"2011","unstructured":"Chng, W. J. et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25, 1026\u20131035 (2011).","journal-title":"Leukemia"},{"key":"76711_CR33","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1080\/10428194.2016.1187275","volume":"57","author":"AG Szabo","year":"2016","unstructured":"Szabo, A. G. et al. Overexpression of c-Myc is associated with adverse clinical features and worse overall survival in multiple myeloma. Leuk. Lymphoma 57, 2526\u20132534 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"76711_CR34","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"76711_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00316-z","volume":"10","author":"J Calder","year":"2021","unstructured":"Calder, J. et al. Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4. Oncogenesis 10, 27 (2021).","journal-title":"Oncogenesis"},{"key":"76711_CR36","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","volume":"16","author":"AM Kurimchak","year":"2016","unstructured":"Kurimchak, A. M. et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 16, 1273\u20131286 (2016).","journal-title":"Cell Rep."},{"key":"76711_CR37","doi-asserted-by":"publisher","first-page":"e0202436","DOI":"10.1371\/journal.pone.0202436","volume":"13","author":"D McAnally","year":"2018","unstructured":"McAnally, D. et al. Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. PLoS ONE 13, e0202436 (2018).","journal-title":"PLoS ONE"},{"key":"76711_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1242\/dmm.003160","volume":"2","author":"JA Fowler","year":"2009","unstructured":"Fowler, J. A., Mundy, G. R., Lwin, S. T., Lynch, C. C. & Edwards, C. M. A murine model of myeloma that allows genetic manipulation of the host microenvironment. Dis. Models Mech. 2, 604\u2013611 (2009).","journal-title":"Dis. Models Mech."},{"key":"76711_CR39","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1172\/JCI126327","volume":"130","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. J. Clin. Investig. 130, 1782\u20131792 (2020).","journal-title":"J. Clin. Investig."},{"key":"76711_CR40","first-page":"6934183","volume":"2017","author":"T Nishihori","year":"2017","unstructured":"Nishihori, T. & Shain, K. Insights on genomic and molecular alterations in multiple myeloma and their incorporation towards risk-adapted treatment strategy. Int. J. Genom. 2017, 6934183 (2017).","journal-title":"Int. J. Genom."},{"key":"76711_CR41","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1158\/0008-5472.CAN-12-1118","volume":"72","author":"S Chen","year":"2012","unstructured":"Chen, S. et al. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 72, 4225\u20134237 (2012).","journal-title":"Cancer Res."},{"key":"76711_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","volume":"9","author":"JG Turner","year":"2016","unstructured":"Turner, J. G. et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J. Hematol. Oncol. 9, 73 (2016.","journal-title":"J. Hematol. Oncol."},{"key":"76711_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/aps.2011.143","volume":"33","author":"R Zeng","year":"2012","unstructured":"Zeng, R., Chen, Y., Zhao, S. & Cui, G. H. Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1. Acta Pharmacol. Sin. 33, 91\u2013100 (2012).","journal-title":"Acta Pharmacol. Sin."},{"key":"76711_CR44","doi-asserted-by":"publisher","first-page":"41535","DOI":"10.18632\/oncotarget.6365","volume":"6","author":"KM Dykstra","year":"2015","unstructured":"Dykstra, K. M., Allen, C., Born, E. J., Tong, H. & Holstein, S. A. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Oncotarget 6, 41535\u201341549 (2015).","journal-title":"Oncotarget"},{"key":"76711_CR45","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2014-03-564534","volume":"124","author":"S Chen","year":"2014","unstructured":"Chen, S. et al. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124, 2687\u20132697 (2014).","journal-title":"Blood"},{"key":"76711_CR46","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/15548627.2014.998892","volume":"11","author":"Y Dai","year":"2015","unstructured":"Dai, Y. & Grant, S. BCL2L11\/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy 11, 416\u2013418 (2015).","journal-title":"Autophagy"},{"key":"76711_CR47","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl, D. T. et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy 10, 1380\u20131390 (2014).","journal-title":"Autophagy"},{"key":"76711_CR48","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3892\/ijmm.2013.1299","volume":"31","author":"H Zhang","year":"2013","unstructured":"Zhang, H. et al. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro. Int. J. Mol. Med. 31, 1127\u20131134 (2013).","journal-title":"Int. J. Mol. Med."},{"key":"76711_CR49","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3324\/haematol.2012.064923","volume":"97","author":"LI Aronson","year":"2012","unstructured":"Aronson, L. I. & Davies, F. E. DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica 97, 1119\u20131130 (2012).","journal-title":"Haematologica"},{"key":"76711_CR50","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.exphem.2014.06.005","volume":"42","author":"M Tucci","year":"2014","unstructured":"Tucci, M. et al. An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. Exp. Hematol. 42, 897\u2013908 (2014).","journal-title":"Exp. Hematol."},{"key":"76711_CR51","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/leu.2013.150","volume":"27","author":"LI Aronson","year":"2013","unstructured":"Aronson, L. I., Davenport, E. L., Mirabella, F., Morgan, G. J. & Davies, F. E. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K\/mTOR inhibition in myeloma cells. Leukemia 27, 2397\u20132403 (2013).","journal-title":"Leukemia"},{"key":"76711_CR52","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-17-0502","volume":"77","author":"A Silva","year":"2017","unstructured":"Silva, A. et al. An ex vivo platform for the prediction of clinical response in multiple myeloma. Cancer Res. 77, 3336\u20133351 (2017).","journal-title":"Cancer Res."},{"key":"76711_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102716","volume":"54","author":"P Sudalagunta","year":"2020","unstructured":"Sudalagunta, P. et al. A pharmacodynamic model of clinical synergy in multiple myeloma. EBioMedicine 54, 102716 (2020).","journal-title":"EBioMedicine"},{"key":"76711_CR54","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nature13492","volume":"513","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 513, 440\u2013443 (2014).","journal-title":"Nature"},{"key":"76711_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fonc.2017.00051","volume":"7","author":"SG Mathiassen","year":"2017","unstructured":"Mathiassen, S. G., De Zio, D. & Cecconi, F. Autophagy and the cell cycle: a complex landscape. Front. Oncol. 7, 51 (2017).","journal-title":"Front. Oncol."},{"key":"76711_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.molcel.2019.10.016","volume":"77","author":"RI Odle","year":"2020","unstructured":"Odle, R. I. et al. An mTORC1-to-CDK1 switch maintains autophagy suppression during mitosis. Mol. Cell 77, 228\u2013240 (2020).","journal-title":"Mol. Cell"},{"key":"76711_CR57","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.molcel.2010.05.009","volume":"38","author":"T Furuya","year":"2010","unstructured":"Furuya, T. et al. Negative regulation of Vps34 by Cdk-mediated phosphorylation. Mol. Cell 38, 500\u2013511 (2010).","journal-title":"Mol. Cell"},{"key":"76711_CR58","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/cdd.2010.191","volume":"18","author":"R Kang","year":"2011","unstructured":"Kang, R., Zeh, H. J., Lotze, M. T. & Tang, D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18, 571\u2013580 (2011).","journal-title":"Cell Death Differ."},{"key":"76711_CR59","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.celrep.2017.08.048","volume":"20","author":"S Goruppi","year":"2017","unstructured":"Goruppi, S. et al. The ULK3 kinase is critical for convergent control of cancer-associated fibroblast activation by CSL and GLI. Cell Rep. 20, 2468\u20132479 (2017).","journal-title":"Cell Rep."},{"key":"76711_CR60","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/jcb.23240","volume":"112","author":"D Zhang","year":"2011","unstructured":"Zhang, D. et al. shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis. J. Cell Biochem. 112, 3140\u20133150 (2011).","journal-title":"J. Cell Biochem."},{"key":"76711_CR61","first-page":"77","volume":"2","author":"E Joyce","year":"2013","unstructured":"Joyce, E., Fabre, A. & Mahon, N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy. Eur. Heart J. Acute Cardiovasc. Care 2, 77\u201383 (2013).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"76711_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.mayocpiqo.2020.10.005","volume":"5","author":"IM Tleyjeh","year":"2021","unstructured":"Tleyjeh, I. M. et al. Cardiac toxicity of chloroquine or hydroxychloroquine in patients with COVID-19. Mayo Clin. Proc. Innov. Qual. Outcomes 5, 137\u2013150 (2021).","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"76711_CR63","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1042\/BCJ20210257","volume":"478","author":"S Mathea","year":"2021","unstructured":"Mathea, S. et al. Conformational plasticity of the ULK3 kinase domain. Biochem. J. 478, 2811\u20132823 (2021).","journal-title":"Biochem. J."},{"key":"76711_CR64","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.3390\/cells11192996","volume":"11","author":"Y Lei","year":"2022","unstructured":"Lei, Y., Zhang, E., Bai, L. & Li, Y. Autophagy in cancer immunotherapy. Cells 11, 2996 (2022).","journal-title":"Cells"},{"key":"76711_CR65","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood.2025029921","volume":"147","author":"MB Meads","year":"2026","unstructured":"Meads, M. B. et al. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood 147, 497\u2013512 (2026).","journal-title":"Blood"},{"key":"76711_CR66","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/blood-2018-06-859686","volume":"133","author":"J Zhuang","year":"2019","unstructured":"Zhuang, J. et al. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood 133, 1572\u20131584 (2019).","journal-title":"Blood"},{"key":"76711_CR67","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.yexmp.2005.07.004","volume":"80","author":"W Zhu","year":"2006","unstructured":"Zhu, W. et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp. Mol. Pathol. 80, 267\u2013274 (2006).","journal-title":"Exp. Mol. Pathol."},{"key":"76711_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20962-6","volume":"12","author":"JJ McGuire","year":"2021","unstructured":"McGuire, J. J. et al. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis-resistant bone metastatic prostate cancer. Nat. Commun. 12, 723 (2021).","journal-title":"Nat. Commun."},{"key":"76711_CR69","doi-asserted-by":"publisher","first-page":"41827","DOI":"10.18632\/oncotarget.18103","volume":"8","author":"G Shay","year":"2017","unstructured":"Shay, G. et al. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment. Oncotarget 8, 41827\u201341840 (2017).","journal-title":"Oncotarget"},{"key":"76711_CR70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4161\/15548627.2014.984273","volume":"11","author":"AA Kraya","year":"2015","unstructured":"Kraya, A. A. et al. Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy 11, 60\u201374 (2015).","journal-title":"Autophagy"},{"key":"76711_CR71","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/bloodadvances.2019000374","volume":"3","author":"S Grieve","year":"2019","unstructured":"Grieve, S. et al. TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC. Blood Adv. 3, 3613\u20133625 (2019).","journal-title":"Blood Adv."},{"key":"76711_CR72","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan, F. et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109, 1692\u20131700 (2007).","journal-title":"Blood"},{"key":"76711_CR73","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/1947-2714.100998","volume":"4","author":"T Mahmood","year":"2012","unstructured":"Mahmood, T. & Yang, P. C. Western blot: technique, theory, and troubleshooting. N. Am. J. Med. Sci. 4, 429\u2013434 (2012).","journal-title":"N. Am. J. Med. Sci."},{"key":"76711_CR74","doi-asserted-by":"publisher","first-page":"101512","DOI":"10.1016\/j.xpro.2022.101512","volume":"3","author":"M Beyer","year":"2022","unstructured":"Beyer, M. & Kramer, O. H. RNA interference protocol to silence oncogenic drivers in leukemia cell lines. STAR Protoc. 3, 101512 (2022).","journal-title":"STAR Protoc."},{"key":"76711_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1107\/S0907444909047374","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D Struct. Biol. 66, 133\u2013144 (2010).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"76711_CR76","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Struct. Biol. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"76711_CR77","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Struct. Biol. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"76711_CR78","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039\u20131045 (2011).","journal-title":"Nat. Biotechnol."},{"key":"76711_CR79","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/1535-7163.MCT-16-0315-T","volume":"16","author":"M Tauro","year":"2017","unstructured":"Tauro, M. et al. Bone-seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth. Mol. Cancer Ther. 16, 494\u2013505 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"76711_CR80","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"},{"key":"76711_CR81","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-1-0716-1028-2_11","volume":"2230","author":"Y Kim","year":"2021","unstructured":"Kim, Y., Brodt, M. D., Tang, S. Y. & Silva, M. J. MicroCT for scanning and analysis of mouse bones. Methods Mol. Biol. 2230, 169\u2013198 (2021).","journal-title":"Methods Mol. Biol."},{"key":"76711_CR82","volume":"101","author":"A Silva","year":"2015","unstructured":"Silva, A., Jacobson, T., Meads, M., Distler, A. & Shain, K. An organotypic high throughput system for characterization of drug sensitivity of primary multiple myeloma cells. J. Vis. Exp. 101, e53070 (2015).","journal-title":"J. Vis. Exp."},{"key":"76711_CR83","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151713","volume":"6","author":"AGM Mostofa","year":"2021","unstructured":"Mostofa, A. G. M. et al. Plasma cell dependence on histone\/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight 6, e151713 (2021).","journal-title":"JCI Insight"},{"key":"76711_CR84","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1172\/JCI122533","volume":"128","author":"Y Ren","year":"2018","unstructured":"Ren, Y. et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J. Clin. Investig. 128, 5517\u20135530 (2018).","journal-title":"J. Clin. Investig."},{"key":"76711_CR85","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","volume":"35","author":"X Zhao","year":"2019","unstructured":"Zhao, X. et al. BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in B cell lymphoma models. Cancer Cell 35, 752\u2013766 (2019).","journal-title":"Cancer Cell"},{"key":"76711_CR86","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020003597","volume":"5","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-\u03baB- and caspase-8-dependent mechanisms. Blood Adv. 5, 3776\u20133788 (2021).","journal-title":"Blood Adv."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76711-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:30:50Z","timestamp":1790479850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76711-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76711"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76711-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7160521\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.H.S. reports honoraria from Bristol Myers Squibb\/Celgene, Janssen, Adaptive, Sanofi, GlaxoSmithKline, Takeda, and Amgen, as well as research funding to the institution from AbbVie and Karyopharm. F.L.L. reports scientific advisory roles and\/or consulting fees from Adaptive Biotechnologies, Allogene, Amgen, AstraZeneca, Bluebird Bio, Bristol Myers Squibb (BMS), Calibr, Caribou, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Miltenyi, Novartis, Sana, Pfizer, and Poseida. He serves on the Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee. His institution has received research funding or contracts from 2SeventyBio, Allogene, BMS, Incyte, Kite Pharma, the Leukemia & Lymphoma Society (Scholar in Clinical Research award; PI: Locke), the Mark Foundation, and the National Cancer Institute. He is named on several unlicensed institutional patents in the field of cellular immunotherapy. He has also engaged in educational or editorial activities with Aptitude Health, the American Society of Hematology (ASH), the American Society for Transplantation and Cellular Therapy (ASTCT), Clinical Care Options Oncology, and the Society for Immunotherapy of Cancer (SITC). H.R.L. and N.J.L. are named as inventors on the issued patents for Dual BRD4 kinase inhibitors, issued patents US10,738,016 and US10,106,507B2. H.R.L., N.J.L., C.L., and M.T. are named inventors on ULK3 inhibitors, patent application: WO2024035771, US Patent 12,391,676, which describes MA9-060. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10142"}}